Ftse Mib
33.746,66
-1,60%
DAX
17.932,17
-1,10%
S&P 500
5.018,39
-0,34%
NASDAQ Composite
15.605,48
-0,33%
Bitcoin
58.443,32
0,35%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Acasti Pharma Inc (ACST) Acasti Pharma Inc (ACST) Notizie

Acasti Pharma Inc

ACST
2,8501
0,0701 (2,52%)
Dopo l'orario di negoziazione
Ultimo aggiornamento: 00:13:32
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
12/2/202414:00EDGAR2Form 8-K - Current report
12/2/202413:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/1/202414:00EDGAR2Form 3 - Initial statement of beneficial ownership of..
08/1/202413:30EDGAR2Form 8-K - Current report
20/12/202322:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/12/202322:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/12/202322:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/12/202313:30EDGAR2Form 8-K - Current report
13/11/202313:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
23/10/202322:30EDGAR2Form 8-K - Current report
16/10/202322:31EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
11/10/202322:30EDGAR2Form 8-K - Current report
06/10/202322:30EDGAR2Form S-3 - Registration statement under Securities Act of..
28/9/202301:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/9/202314:10EDGAR2Form 8-K - Current report
05/9/202321:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/8/202323:01EDGAR2Form S-8 - Securities to be offered to employees in employee..
25/8/202322:21EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
25/8/202322:15EDGAR2Form DEF 14A - Other definitive proxy statements
11/8/202313:31EDGAR2Form 8-K - Current report
11/8/202313:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
24/7/202323:30EDGAR2Form 8-K - Current report
18/7/202322:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/7/202322:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/7/202322:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/7/202322:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/7/202322:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/7/202322:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/7/202322:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/7/202315:00PRNUSAcasti Announces WuXi Clinical as CRO to Conduct STRIVE-ON..
07/7/202314:30EDGAR2Form 8-K - Current report
07/7/202314:00PRNUSAcasti Pharma Announces 1-for-6 Reverse Stock Split
05/7/202322:00EDGAR2Form 8-K - Current report
05/7/202315:00PRNUSAcasti Announces Alignment with FDA on GTX-104 Pivotal Phase..
23/6/202313:00PRNUSAcasti Pharma Reports Fiscal Year 2023 Operational Results
22/6/202315:00PRNUSAcasti Announces Appointment of New Scientific Advisory..
17/5/202315:00PRNUSAcasti to Participate in the Lytham Partners Spring 2023..
08/5/202313:00PRNUSAcasti Successfully Submits Pivotal GTX-104 Phase 3 Safety..
Apertura: 2,77 Min: 2,70 Max: 2,93
Chiusura: 2,78

La tua Cronologia

NASDAQ
ACST
Acasti Pharma
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network